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OBJECTIVES To test the feasibility of myocardial angiogenic gene expression using a novel catheter-based
transendocardial injection system.
BACKGROUND Angiogenesis has been induced by direct injection of growth factors into ischemic myocar-
dium during open-heart surgery. Catheter-based transendocardial injection of angiogenic
factors may provide equivalent benefit without need of surgery.
METHODS A new guidance system for intramyocardial therapy utilizes magnetic fields and catheter-tip
sensors to locate a position in space and reconstruct three-dimensional left ventricular (LV)
electromechanical maps without using fluoroscopy. A retractable 27G needle was coupled
with the guidance system for LV transendocardial injection. In 12 pigs, the catheter was used
to inject 0.1 ml of methylene-blue (MB) dye and 8 pigs had myocardial injections of
adenoviral vector (1 3 1010 particles per site) containing the LacZ transgene. Ten pigs
underwent catheter-based transendocardial injection and six pigs were injected using
transepicardial approach with the gene encoding adenovirus vascular endothelial growth
factor-121 (Ad.VEGF121; 1 3 10
10 viral particles 3 6 sites) and sacrificed at 24 h. Injection
sites were identified with ultraviolet light by coinjection of fluorescent beads.
RESULTS Overall, 138 of 152 attempted injection MB tracks (91%) were found after sacrifice. Tissue
staining was 7.1 6 2.1 mm in depth and 2.3 6 1.8 mm in width. No animal had pericardial
effusion or tamponade. In Ad.LacZ injected animals, gross pathology showed positive
staining in injected zones, and histology confirmed positive myocyte staining. Adenovirus
vascular endothelial growth factor-121 injected sites showed high levels of VEGF121
production that was of similar magnitude whether injected using the transendocardial
(880.4 6 412.2 pg VEGF121/mg protein) or transepicardial (838.3 6 270 pg VEGF121/mg
protein) delivery approach (p 5 0.62).
CONCLUSIONS Using this magnetic guidance catheter-based navigational system, transgenes can effectively
be transfected into designated myocardial sites. Thus, if it is determined that direct
intramyocardial injection of angiogenic factors enhances collateral function in patients, this
less invasive catheter-based system offers a similar gene delivery efficiency and, thus, may
have clear advantages compared with the surgically-based transepicardial injection approach.
(J Am Coll Cardiol 2000;35:1031–9) © 2000 by the American College of Cardiology
The use of recombinant genes or growth-factors to enhance
myocardial collateral blood vessel function may represent a
new approach to the treatment of cardiovascular disease (1).
Proof of this concept has been demonstrated in animal
models of myocardial ischemia (2–7), and clinical trials are
underway (8–10). Most strategies for transcatheter delivery
of angiogenic factors have employed an intracoronary route,
which may have limitations due to imprecise localization of
genes or proteins and systemic delivery to noncardiac tissue.
Thus, it would be desirable to have the capacity for direct
delivery of angiogenic factors or genes to precisely defined
regions of the myocardium rather than to the entire heart
and, thereby, to minimize the potential for systemic expo-
sure (11). The effect of direct intraoperative intramyocardial
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injection of angiogenic factors on collateral function has
been studied in a porcine model of myocardial ischemia;
open chest, transepicardial administration of an adenoviral
vector containing a transgene encoding an angiogenic pep-
tide resulted in enhanced collateral function (7). Angiogen-
esis was also reported to occur with direct intramyocardial
injection of an angiogenic peptide (8) or a plasmid vector (9)
during open heart surgery in patients. Ideally, a catheter-
based intramyocardial injection system could provide accu-
rate intramyocardial injection of angiogenic factors (genes
or peptides) without the need for surgery and general
anesthesia (12).
This report describes a new electromagnetic-based plat-
form system developed for catheter-based intramyocardial
injection that may be used to achieve therapeutic angiogen-
esis. The guidance system (NOGA, Biosense-Webster,
Diamond Bar, California) utilizes low-intensity magnetic
field energy and sensor tipped catheters to locate the
catheter position in space (13–18). Three-dimensional (D)
electromechanical maps of the left ventricle (LV) help to
differentiate between healthy and infarcted myocardium and
can be used to identify most ischemic target regions without
using fluoroscopy (16,18). This system was integrated with
an injecting catheter having a 27G needle for intramyocar-
dial delivery of potentially therapeutic agents.
The purpose of this study was to:
1) evaluate the feasibility and safety of electromagnetic
guidance for a catheter-based transendocardial injection
system in normal and ischemic myocardium,
2) assess the accuracy of the system to locate, in real time,
the sites of intramyocardial injection,
3) identify local diffusion of a fluid (dye tracer) from the
injection site into myocardial tissue,
4) determine whether gene transfer into normal or ischemic
myocardium can be achieved using this integrated cath-
eter system that results in successful gene expression (as
assessed by LacZ reporter gene activity), and
5) determine if a therapeutically relevant gene can be
effectively delivered via the electromagnetic guidance
and injection catheter and can be expressed at high
levels.
The latter was achieved by injecting transendocardially an
adenoviral vector carrying the gene encoding vascular endo-
thelial growth factor-121 (Ad.VEGF121) and comparing
the levels of Ad.VEGF121 expression to those obtained by a
surgical based transepicardial injection approach.
METHODS
Electromagnetic-guided LV mapping and injection sys-
tem. As described previously (13–18), the electromechan-
ical mapping system uses:
1) a location pad containing three coils generating ultralow
magnetic field energy,
2) a stationary reference catheter with a miniature magnetic
field sensor located on the body surface,
3) a navigation sensor mapping catheter (7F) with a
deflectable-tip and electrodes providing endocardial sig-
nals, and
4) a workstation for information processing and 3D LV
reconstruction.
The mapping catheter was introduced retrograde across the
aortic valve into the LV. The initial three points outlining
the boundaries of the LV (apex, aortic outflow and mitral
inflow) were acquired with fluoroscopic guidance. Subse-
quently, no fluoroscopy was needed to acquire additional
sampled points within the LV chamber. The mapping
process proceeded only when the catheter tip was stable on
the endocardial surface as evidenced by local activation time,
location, loop and cycle length stability parameters. The
system used a triangulation algorithm to reconstruct the LV
anatomy, which was presented in real-time on a worksta-
tion. Once all endocardial regions were represented on the
map, the operator completed the reconstruction of the LV
map, the mapping catheter was removed from the LV and
replaced by an 8F injection catheter (Biosense; Webster,
California). The injection catheter was a mapping catheter
modified to integrate a retractable 27G needle for LV
intramyocardial injection. The catheter “dead-space” was
0.1 ml and was flushed by 0.1 ml using the injection
material before its endovascular insertion. The needle was
controlled by a handle mechanism that was located proximal
to the standard deflection handle. The injection had a Luer
fitting for connection to a 1 cc or 3 cc syringe. Standard
manual operation of the syringe attached to the injection
handle delivered the fluid to the myocardium. The operator
of the syringe controlled the dosage using the gradations on
the syringe.
The exact catheter-tip location, orientation and the
injection sites were indicated in real-time on the LV map,
and local electrical and location signals were traced to assure
catheter stability and optimal endocardial contact. Animals
were monitored for systemic blood pressure and surface
electrocardiograms throughout the study protocol and dur-
ing the recovery period. Arrhythmia was evaluated from the
LV mapping catheter data during mapping and by electro-




ELISA 5 enzyme-linked immunosorbent assay
LV 5 left ventricle
MB 5 methylene-blue
PBS 5 phosphate buffered saline
UV 5 ultraviolet
VEGF 5 vascular endothelial growth factor
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Fluid dispersion tests. After adequate anesthesia with
ketamine (20 mg/kg) and xylazine (2 mg/kg) i.m. and
sodium pentobarbital (10 mg/kg) IV, animals (weight 50 to
70 kg) were intubated and received supplemental oxygen at
2 L/min and isoflurane inhalation throughout the proce-
dure. Left ventricular electromechanical mapping was per-
formed followed by intramyocardial injection of 0.1 ml of
methylene-blue (MB) dye (1:10 dilution in normal saline) in
12 healthy anesthetized pigs. Needles were extended into
the myocardium to 3 to 4 mm in two myocardial regions
(i.e., anterior, septum, lateral, inferior or posterior) per
animal. After the injection procedure, all catheters were
removed, and the animals were sacrificed acutely. Injection
sites were localized by gross examination of the endocardial
surface in conjunction with localization data obtained from
the LV maps. The extent of intramyocardial staining
(maximal depth and width) was measured to identify local
diffusion of MB dye tracer from the injection site. In
addition, the success of achieving intramyocardial injection
was assessed based on the number of endomyocardial
injection sites found compared with the number of at-
tempted injection sites.
The needle length, both straight and deflected, at prein-
jection and postinjection was measured before and after
each experiment using a hand caliper to verify potential
deviations from prespecified needle length (3 to 4 mm) or
changes in needle extension during the course of the
experiment.
Evaluation of reporter gene transfer. We next tested the
capacity of the electromagnetic guidance and injection
catheter system to deliver trangenes to ischemic or normal
myocardium. Replication-deficient recombinant Ad. con-
taining the transgene encoding beta-galactosidase (beta-gal;
Ad.LacZ, GenVec Inc., Rockville, Maryland) and contain-
ing a nuclear localization sequence was injected into eight
pigs (weight 50 to 70 kg) in vivo. Four of the eight pigs
underwent induction of myocardial ischemia (see following
text), and four additional pigs had normal hearts. The
replication-deficient recombinant Ad. has been previously
described, and its efficient gene transfer into myocardial
tissue by a direct epicardial injection approach has been
previously demonstrated (11). Myocardial ischemia was
induced in four animals by the application of an ameroid
constrictor placed around the left circumflex artery. The
ameroid constrictor resulted in gradual (14 to 21 days)
coronary artery occlusion and, in pigs, usually produces
chronic ischemia rather than infarction (6,7,18,19). Five
weeks after ameroid placement, the four ischemic pigs
underwent general anesthesia (using the same protocol
specified above) and selective coronary angiography to
document occlusion of the ameroid constrictor site. A left
ventricular electromechanical map was obtained, followed
by injection of Ad.LacZ into the ischemic lateral wall area
using the injection catheter. The ischemic myocardial ter-
ritory was identified as that region of the LV anatomical
map showing impaired mechanical contractility signals (18).
This was located in the lateral wall supplied by the occluded
left circumflex coronary artery.
Each site was injected with 1010 viral particles diluted in
0.1 ml (n 5 6) and 0.2 ml (n 5 2) solution containing
sucrose 3%. Different volumes were used to determine
whether keeping the needle length constant (3 to 4 mm) but
increasing the volume of delivery would provide for greater
gene transfer throughout the thickness of the ventricular
wall without causing perforation of the myocardium. Ani-
mals were sacrificed at 24 h and myocardial tissue was
evaluated for gene expression. Hearts were excised and
underwent ex vivo retrograde perfusion with 200 ml normal
saline. Injection sites were localized according to compara-
tive anatomical and mapping derived measurements (i.e.,
linear distances from anatomical markers such as the
apex and aortic valve and from two additional reference
endocardial points obtained by MB injection into the heart).
Full thickness myocardial samples (5 mm in width) were
obtained from the presumed injection sites. The samples
were fixed in a solution containing 2% formaldehyde and
0.2% glutaraldehyde in phosphate buffered saline (PBS) at
pH 7.4 and cut into sections approximately 2 mm thick.
Sections were then washed three times in PBS and placed
in X-gal histochemical solution containing 5 mmol/L
K4Fe(CN)6, 5 mmol/L K3Fe(CN)6, 1 mmol/L 5 MgCl2
and 1 mg/ml X-gal (5-bromo-4-chloro-3-indoyl-beta-D-
galactopyranoside) in PBS for 24 h. Samples were subse-
quently processed for gross and microscopic histological
analysis.
Evaluation of VEGF121 gene transfer. We tested whether
adenoviral vector carrying the gene encoding Ad.VEGF121
can be effectively delivered via the electromagnetic guidance
and injection catheter and to determine whether the trans-
gene was efficiently expressed. These were assessed by
determining the levels and distribution of VEGF121 protein
expression 24 h later. The ability of the replication deficient
Ad. containing an expression cassette encoding for
VEGF121 (GenVec, Inc., Rockville, Maryland) to enhance
collateral perfusion has been previously described (7). In
order to localize precisely the sites of injection, we used a
technique in which fluorescent microspheres (Flouresbright,
Polysciences Inc., Warrington, Pennsylvania) are mixed
with the adenoviral vector carrying the relevant transgene in
a 1:10 dilution and injected into the myocardium. This
method allows for precise localization of the transfected
tissue.
After harvesting the treated tissue, the site of transfection
can be localized using an ultraviolet (UV) lamp; protein
levels at the precise site of transfection are then determined.
Using this method we tested the capacity of the electromag-
netic guidance and injection catheter system to deliver the
adenoviral VEGF vector to the myocardium of 10 normal
pigs (weight 50 to 70 kg) undergoing catheter-based
Ad.VEGF121 gene delivery. Those results were compared
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with transepicardial Ad.VEGF121 gene delivery via open
chest left thoracotomy performed in six additional pigs. Six
injections were performed per animal. Each site was injected
with 1010 viral particles diluted in 0.1 ml PBS solution.
Three injections were localized to the anterior-septal region
and three others to the inferior or lateral regions. Animals
were sacrificed at 24 h and myocardial tissue was evaluated
for gene expression. Hearts were excised and underwent ex
vivo retrograde perfusion with 200 ml normal saline. All
hearts were sectioned horizontally into 0.5 cm slices from
the apex to the base of the heart. Injection sites were
visualized under UV light and for each bead injection
region. A 1 cm3 central portion (surrounding the beads) was
harvested and two additional lateral adjacent portions were
also harvested to assess spread of VEGF121 protein. Addi-
tional samples were taken from “remote,” presumably non-
transfected, portions of the LV and right ventricle. All
samples were immediately frozen using liquid nitrogen and
kept in 280°C until VEGF protein analysis using enzyme-
linked immunosorbent assay (ELISA).
VEGF121 measurement. Vascular endothelial growth
factor-121 levels were quantified as per the manufacturer’s
instructions using the R&D Systems human VEGF ELISA
kit (#DVE00, R&D Systems, Inc. Minneapolis, Minne-
sota) with the following modification: the VEGF165 used to
generate the standard curve for the assay was replaced with
VEGF121 (#298-VS-005, R&D Systems, Inc. Minneapolis,
Minnesota) to ensure accurate quantification of the desired
VEGF isoform.
Statistical analysis. Nominal values are presented as
means 6 1 standard deviation. Repeated measurements
(pre- versus post-procedure) were compared using repeated
measures analysis of variance. A comparison between peak
VEGF levels in the surgical versus the catheter-based group
was performed using unpaired t test. p , 0.05 was consid-
ered as statistically significant.
RESULTS
Fluid dispersion tests. The injection site was indicated in
real-time on the LV map (Fig. 1). Using the catheter
system, we injected 0.1 ml of MB as dye tracer in 12 pigs
and measured the extent of intramyocardial staining when
the needle was extended 3 to 4 mm (152 injections) into the
myocardium. Staining was 7.1 6 2.1 mm (range 2–11 mm)
in depth and 2.3 6 1.8 mm (range 1 to 9 mm) in its
maximal width. Dye staining of the epicardial surface was
found in only 4 of 152 injections (2.6%). Three of those
were found when the dye was injected into the apical area.
The frequency with which we targeted specific anatomic
injection sites was: anterior 58 (38%), inferior 24 (16%),
posterior 20 (13%), lateral 47 (31%) and apex 3 (2%).
Overall, 138 of 152 attempted injection tracks (91%) were
found immediately after sacrifice, ranging from 78% to
100% per single animal experiment. No animal died during
the injection procedure. No animal had pericardial effusion
or tamponade, and no episodes of sustained ventricular
arrhythmia were noted immediately after intramyocardial
injection. The mean arterial blood pressure (83 6 15 vs.
81 6 17 mm Hg, p 5 0.56) and mean heart rate (86 6 7
vs. 83 6 11 beats/min, p 5 0.52) did not change signifi-
cantly during the injection procedure. There was no signif-
icant change in needle length over the course of the
procedure (3.6 6 0.2 mm before the injection, 3.2 6
0.3 mm after the injection, p 5 0.38). The endomyocardial
surface after injection of MB dye is shown in Figure 2.
Figure 1. A representative electromechanical left ventricle map (right and left oblique projections, A and B, respectively) after
intramyocardial injection of methylene-blue into normal heart showing the ability of the injection device to reach different myocardial
territories (A; anterior-septal zone, B; lateral zone). The voltage amplitudes are color coded, and the exact location of the injection sites
is tagged (brown) on the map in real-time.
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Ad.LacZ gene expression. All eight tested animals sur-
vived the Ad.LacZ injection procedure until sacrifice at
24 h. No episodes of sustained ventricular arrhythmia were
noted immediately after intramyocardial injection or during
the recovery period. After fixation and X-gal staining for
24 h, gross pathology assessment showed that hearts in-
jected with Ad.LacZ had positive blue staining. The beta-
gal staining was mainly confined to approximately one half
of the myocardial thickness, and it had a flame-shaped
appearance. The ability of the system to target the injections
into the ischemic area was demonstrated in all four ischemic
animals. Ischemic myocardium was identified by the pres-
ence of mechanical dysfunction and preserved electrical
activity in the left circumflex arterial distribution (Fig. 3).
Macroscopic and microscopic examples are shown in Figure
4. Similar myocardial X-gal staining pattern was observed
with 0.1 ml compared with 0.2 ml injected volume. Gross
and histologic examination of the hearts injected with
Ad.LacZ showed positive staining in the nuclei and cyto-
plasm of cardiac myocytes (Fig. 4). Inflammatory mononu-
clear cells were often seen around transfected myocytes.
Noninjected myocardial samples from the left and right
ventricles did not show Ad.LacZ positive staining after
exposure to X-gal solution.
Catheter-based (transendocardial) VEGF121 gene trans-
fer. Overall, 60 injections of Ad.VEGF121 have been per-
formed in 10 animals. All animals survived for 24 h until
sacrifice. Using UV light, 59 of the 60 injection sites
(98.3%) were clearly identified (Fig. 5). The transfection
sites seemed discrete and manifested significant VEGF
production in 57/59 sites (96.6%) at the central portion of
injection (880.4 6 412.2 pg VEGF/mg protein). In two
sites, measurable VEGF121 levels were not detectable in
either central or adjacent pieces despite the existence of
beads in those sites. A significant drop-off of VEGF
production was noted even 1 cm to the left (21.4 6 7.9 pg
VEGF121/mg protein) or right (73.3 6 63.3 pg
VEGF121/mg protein) of the injection site (Fig. 6). No
detectable levels of VEGF121 were found in any of the right
Figure 2. (A) The tip of the injection catheter equipped with recording electrodes, a location sensor (hosted within the catheter tip) and
a 27 G needle extending for 3 to 4 cm length. (B) The endocardial surface is displayed after multiple methylene-blue due injections
(arrows). (C) Intramyocardial flame-shaped “signature” of methylene-blue staining in a cross-section.
Figure 3. The ability of the magnetic-guided system to target the injections into the ischemic region of the heart. A representative
electrical map (A; unipolar voltage) and mechanical map (B; local endocardial shortening) after induction of ischemia in the lateral wall
by occlusion of the circumflex artery (left oblique views). The color scale is set between 5 mV (red) to 15 mV (blue/purple) for the voltage
map and between 6% (red) to 12% (blue/purple) for the mechanical map. Note a significant mechanical impairment exists in the lateral
wall (local endocardial shortening ,6%, red zone) secondary to chronic myocardial ischemia, with preserved (normal) voltage potentials
(;15 mV). The sites of injection (dots within the dysfunctional “red” zone) are targeted to the ischemic regions and are shown in real
time on the maps.
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ventricular samples. There were detectable levels of
VEGF121 (39.5 pg VEGF121/mg protein) in only 1 of 10
remote LV samples although no fluorescent beads were
identified in this site. In all other remote sites, no detectable
VEGF121 levels were identified.
Surgical (transepicardial) VEGF121 gene transfer. Over-
all, 36 injections of Ad.VEGF121 were performed in six
animals. All animals survived for 24 h until sacrifice. Using
UV light, all 36 injection sites (100%) were identified. The
transfection sites manifested significant VEGF121 produc-
tion in all 36 sites at the central portion of injection
(838.3 6 270 pg VEGF121/mg protein) (Fig. 6). Impor-
tantly, VEGF121 levels were comparable with those ob-
tained by the transendocardial injections (p 5 0.62 for
comparison between the surgical and catheter-based
groups). Adjacent VEGF121 levels were 10.0 6 3.0 pg/mg
protein (left piece) and 13.0 6 3.0 pg/mg protein (right
piece). Using the surgical injection approach, VEGF121
could be detected in two of six left ventricular “remote”
samples (27.0 and 163.3 pg/mg protein) and in one of six
right ventricular samples (52.4 pg/mg protein).
DISCUSSION
The main findings of this investigation were: 1) the
guided LV mapping technology and injection system
provides an accurate and reliable means of delivering an
injectate transendocardially into the LV, 2) the injection
Figure 4. Gross pathology of heart tissue (cross section) injected with the adenovirus vector containing the LacZ reporter transgene and
subsequently stained with X-gal solution. Note the areas of positive Ad.LacZ dark-blue staining in the lateral (left circumflex distribution)
zone. Microscopic section shows myocytes transfected by Ad.LacZ gene with typical nuclear as well as cytoplasmic staining and
inflammatory infiltrate near transfected myocytes (original magnification 3 100). Ad. 5 adenovirus; L 5 lateral myocardium; S 5 septal
myocardium.
Figure 5. A representative injection site relative to fluorescent
microspheres location shown under ultraviolet light. From each
site, a central piece (C) and adjacent pieces (R and L) were
harvested for vascular endothelial growth factor-121 protein mea-
surement.
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technique caused no serious sequella such as death,
hemodynamically destabilizing arrhythmias or cardiac
tamponade, and 3) this system allows for the injection of
an adenoviral vector containing genes for LacZ or
VEGF121 into designated ischemic myocardial sites and
results in successful gene transfer and protein expression.
Figure 6. Bars showing VEGF121 concentration produced at each site relative to fluorescent bead foci using either transendocardial (upper
panel) or transepicardial (lower panel) injection approaches. Note a significantly higher VEGF121 produced at the central piece where the
endocardial injection was made with lower VEGF121 expression in adjacent sites, with comparable levels achieved with both injection
approaches. VEGF121 5 vascular endothelial growth factor-121.
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Importantly, the VEGF121 results showed much greater
expression at the site of injection, with a significant
‘drop-off’ of VEGF production even 1 cm from the
injection site. Our study also shows that this less invasive
catheter-based approach for gene delivery enables an
equivalent gene transfection efficiency and gene expres-
sion compared with a surgical-based transepicardial in-
jection approach. Thus, we believe that this strategy of
gene delivery offers a clear advantage over a surgical-based
approach for use in therapeutic myocardial angiogenesis.
Previous animal studies have proven the feasibility of
enhancing collateral function by delivery of angiogenic
factors to the myocardium. This has been achieved either by
intracoronary injection of the angiogenic factor at catheter-
ization or by direct intramyocardial injection after thoracot-
omy (2–7). Successful angiogenesis has resulted from deliv-
ery of either angiogenic proteins or plasmids or adenoviral
vectors containing transgenes that encode angiogenic pro-
teins. Currently, however, it is unknown which is the most
effective and safe delivery strategy (i.e., intracoronary vs.
intramyocardial injection) to induce clinically important
therapeutic angiogenic responses in ischemic myocardium.
A theoretical advantage of direct intramyocardial injec-
tion of angiogenic factors compared with intracoronary
delivery is that with intracoronary injection, during its first
pass, a significant amount of the angiogenic factor will not
be taken up from the vascular compartment by the heart
and, therefore, will be delivered to other tissues (20). It
would, thus, appear desirable, if possible, to deliver all of the
angiogenic material directly into the target tissue. This
approach has been successfully accomplished using an ad-
enoviral vector containing the VEGF121 transgene that was
directly injected into ischemic myocardium of pig hearts
during thoracotomy (7). Both myocardial perfusion and
function in this model were significantly improved (7). The
feasibility and safety of such direct VEGF121 transgene
delivery approach in patients has been demonstrated (10).
The first clinical experience with intramyocardial injection
of an angiogenic factor was recently reported. Recombinant
human fibroblast growth factor-1 was directly injected into
the myocardium just distal to the anastomotic site of the left
internal mammary and anterior descending coronary artery
(8). Twelve-weeks later, angiographic studies were inter-
preted as being compatible with the formation of a collateral
arterial network around the injection site. Another prelim-
inary experience with either naked gene transfer for
VEGF165 via a minimally invasive chest wall incision
suggested an improvement in anginal symptoms and myo-
cardial perfusion in patients with chronic refractory myo-
cardial ischemia (9).
Although of potential clinical importance, the practical
application of the transthoracic transepicardial strategy for
therapeutic angiogenesis is limited due to the risks and
expenses incurred by the invasive nature of the procedure. It
was, therefore, the purpose of this investigation to test the
efficacy and safety of an electromagnetic guidance system for
catheter-based intramyocardial injection. The feasibility of
catheter-mediated direct injection of an Ad. vector inducing
gene expression in the ventricle has been previously dem-
onstrated (12,21). Our study was the first study of using the
electromagnetic-guided percutaneous approach to deliver
proangiogenic relevant transgenes into the myocardium.
The potential advantage of such an approach is that it allows
precise localization of gene transfer directed towards the
most ischemic myocardial regions while avoiding multiple
same-site injections. This strategy may enhance the thera-
peutic benefit and improve procedural safety of catheter-
based gene delivery.
Study limitations. Our study is limited by the lack of
evaluation of systemic transgene delivery and expression.
Until such an experiment is completed, we cannot defini-
tively conclude that our approach totally limits gene delivery
to the target tissue. In this regard, in 5% to 10% of
injections, no track was found. This raises the possibility of
systemic delivery of the genetic material, if indeed the
reason for the failure was not “obstruction” with no material
ejected, but rather that material was injected into the LV
and thereby delivered systemically. Another limitation was
the lack of precise pressure control due to manual delivery.
The pressure effect may account for the fact that the needle
can create deeper tracks and staining zones than its actual
extension. Our study lacked histopathology evaluation com-
paring MB staining versus the myocardial transduction
noted after Ad. injections. Finally, our study was not
designed to explore whether the minimal inflammatory
tissue response noted at 24 h after Ad. injection may have
been associated with viral transduction, the results of cath-
eter injection itself or both.
Conclusions. Intramyocardial delivery of angiogenic fac-
tors via the transendocardial catheter system appears safe
and suitable for delivering therapeutic agents into the
myocardium. At present, catheter design is in a rapid stage
of evolution to reduce potential tissue trauma and to ensure
reproducibility of the injection parameters. Ultimately, with
proper physician training, this system should permit the
routine safe transendocardial delivery of therapeutic agents
into the LV myocardium. If the biologic and clinical
importance of angiogenic treatment is ultimately demon-
strated, the system we describe in this report may constitute
an important new strategy of treating patients with myo-
cardial ischemic syndromes.
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